Netflix Q2 Profit Warning Sends Shares Tumbling as Reed Hastings Exits 
Elliott Investment Takes ~3% Stake in Daikin, Pushes for Buybacks and Strategic Overhaul 
Uber Bets Big on Autonomous Vehicles with $10 Billion Commitment 
ASML Raises 2026 Revenue Outlook as AI Chip Demand Surges 
Federal Judge Dismisses DOJ Lawsuit Attempting to Block Hawaii's Climate Case Against Oil Giants 
Iran War Drives Asia's Plastic Crisis — and a Green Packaging Boom 
CATL Stock Hits Record High After Q1 2025 Earnings Surge 
Pentagon Taps Auto Giants to Supercharge U.S. Weapons Production 
Goldman Sachs FICC Revenue Falls 10% Amid Iran War Market Volatility 
NiSource Signs Long-Term Energy Deals with Alphabet and Amazon to Power Indiana Data Centers 
Japan to Subsidize Sony's Image Sensor Plant in Kumamoto with $380 Million 
AEVEX Raises $320 Million in IPO Amid Surging Defense Sector Demand 
Tesla's Terafab: AI Chip Factory Eyes Taiwan's Semiconductor Talent 
Elon Musk's Terafab Foundry Courts Top Chipmaking Giants for AI Self-Sufficiency Push 
Japan Opens Arms Export Floodgates: New Policy Draws Global Defense Interest 
CSN's Cement Unit Sale Could Exceed $2 Billion as Global Giants Circle 
Want to cut your energy bills? Here’s how five experts are doing it 
SAN DIEGO, May 31, 2017 -- aTyr Pharma, Inc. (Nasdaq:LIFE), a biotherapeutics company engaged in the discovery and development of Physiocrine-based therapeutics to address severe, rare diseases, today announced the Company's participation at the Jefferies 2017 Global Healthcare Conference to be held in New York City from June 6 - 9, 2017.
The aTyr management team will present an overview of the Company during a presentation at 2:00 p.m. ET on Friday, June 9, 2017. The presentation will be webcast live through the "Investors" section of the aTyr Pharma website at www.atyrpharma.com. An audio replay will be available for at least 30 days following the initial presentation webcast.
About aTyr Pharma
aTyr Pharma is engaged in the discovery and clinical development of innovative medicines for patients suffering from severe, rare diseases using its knowledge of Physiocrine biology, a newly discovered set of physiological pathways. To date, the Company has generated three innovative therapeutic candidate programs based on its knowledge of Physiocrine biology in three different therapeutic areas. aTyr has built an intellectual property estate, to protect its pipeline, comprising over 190 issued patents or allowed patent applications that are owned or exclusively licensed, including over 300 potential Physiocrine-based protein compositions. aTyr's key programs are currently focused on severe, rare diseases characterized by immune imbalance for which there are currently limited or no treatment options. For more information, please visit http://www.atyrpharma.com.
Contact: Mark Johnson Sr. Director, Investor Relations [email protected] 858-223-1163
